[1]张玲玲,张小霞,於潇潇,等.非小细胞肺癌患者血浆miR-520f，miR-143-3p表达与病理特征和预后的相关性研究[J].现代检验医学杂志,2022,37(03):69-72.[doi:10.3969/j.issn.1671-7414.2022.03.014]
　ZHANG Ling-ling,ZHANG Xiao-xia,YU Xiao-xiao,et al.Correlation Study on Plasma miR-520f and miR-143-3p Expression with Pathological Features and Prognosis in Patients with Non-small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2022,37(03):69-72.[doi:10.3969/j.issn.1671-7414.2022.03.014]
点击复制

非小细胞肺癌患者血浆miR-520f，miR-143-3p表达与病理特征和预后的相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第37卷
期数:
2022年03期
页码:
69-72
栏目:
论　著
出版日期:
2022-05-15

文章信息/Info

Title:
Correlation Study on Plasma miR-520f and miR-143-3p Expression with Pathological Features and Prognosis in Patients with Non-small Cell Lung Cancer
文章编号:
1671-7414（2022）03-069-05
作者:
张玲玲; 张小霞; 於潇潇; 葛　琴
（南通市肿瘤医院检验科，江苏南通 226361）
Author(s):
ZHANG Ling-ling;  ZHANG Xiao-xia;  YU Xiao-xiao;  GE Qin
（Department of Laboratory Medicine, Nantong Tumor Hospital, Jiangsu Nantong 226361,China）
关键词:
非小细胞肺癌; 微小核糖核酸
分类号:
R734.2；R730.43
DOI:
10.3969/j.issn.1671-7414.2022.03.014
文献标志码:
A
摘要:
目的　探讨血浆微小核糖核酸（ micro RNA，miRNA）-520f和 miR-143-3p表达与非小细胞肺癌（ non-small cell lung cancer，NSCLC）患者病理特征和预后的关系。方法　选择 2015年 1月～ 2017年 1月南通市肿瘤医院收治的 81例首次确诊 NSCLC患者（ NSCLC组）和 62例体检正常者（对照组）。均采集外周血浆，采用实时荧光定量 PCR (qRT-PCR)检测 miR-520f和 miR-143-3p表达，分析 miR-520f和 miR-143-3p表达与 NSCLC临床病理特征的关系。以随访期间肿瘤复发、远处转移、死亡为终点事件， Kaplan-Meier和 COX回归分析 miR-520f和 miR-143-3p表达与 NSCLC患者预后的关系。结果　NSCLC组血浆 miR-520f（1.82±0.32），miR-143-3p（0.35±0.06）表达低于对照组（ 2.51±0.49，0.94±0.11），差异均有统计学意义（ t =10.160，40.986，均 P＜ 0.05）。miR-520f表达与 NSCLC患者 TNM分期、淋巴结转移有关（ t=4.335, 4.983，均 P＜ 0.05），miR-143-3p表达与分化程度、 TNM分期和淋巴转移有关（ t =5.035, 3.349, 7.604，均 P＜ 0.05），差异均有统计学意义。 Kaplan-Meier生存分析结果显示低 miR-520f（58.97%，76.92%)和 miR-143-3p（58.33%，75.00%）表达， NSCLC患者无疾病进展（ progression-free survival，PFS)与总体生存（ overall survival，OS）生存率低于高 miR-520f表达（ 90.48%，95.24%）和高 miR-143-3p表达（ 88.89%，95.56%），差异均有统计学意义（Log Rank χ2=9.270，5.303，P=0.02，0.021；Log Rnakχ2=9.079，6.857，P=0.003，0.009）。淋巴结转移（OR=1.680， 95%CI：1.423～ 1.956），miR-520f（OR=1.836，95%CI：1.658～ 2.358），miR-143-3p（OR=2.169，95%CI：2.015～ 3.959）与 NSCLC不良预后有关（均 P＜ 0.05）。结论　miR-520f和 miR-143-3p在 NSCLC患者中表达降低，且与 NSCLC细胞恶性增殖和侵袭行为以及 NSCLC患者不良预后有关。
Abstract:
Objective　To investigate the relationship between the expression of plasma miR-520f and miR-143-3p and the pathological features and prognosis of non-small cell lung cancer (NSCLC) patients. Methods　From January 2015 to January 2017, 81 patients with NSCLC diagnosed for the first time (NSCLC group) and 62 normal subjects (control group) were selected from Nantong Tumor Hospital. Peripheral blood was collected, and the expressions of miR-520f and miR-143-3p were detected by real-time fluorescence quantitative PCR (qRT-PCR), and the relationship between the expressions of miR-520f and miR-143- 3p and the clinicopathological characteristics of NSCLC was analyzed. With tumor recurrence, distant metastasis, and death as endpoint events during follow-up, Kaplan-Meier and COX regression analysis were conducted to analyze the relationship between miR-520f and miR-143-3p expression and the prognosis of NSCLC patients. Results　The expression of plasma miR- 520f（1.82±0.32）and miR-143-3p（0.35±0.06) was lower than that in the control group（2.51±0.49，0.94±0.11），the differences were statistically significant(t=10.160 ，40.986，all P ＜ 0.05). The expression of miR-520f was associated with the TNM stage and lymph node metastasis of NSCLC patients （t =4.335,4.983，all P ＜ 0.05）, and the expression of miR-143-3p was associated with the degree of differentiation, TNM stage and lymph node metastasis （t =5.035, 3.349, 7.604，all P ＜ 0.05）, the differences were statistically significant，respectively. Kaplan-Meier survival analysis showed that the PFS and OS survival rates of NSCLC patients with low miR-520f（58.97%，76.92%) and miR-143-3p（58.33%，75.00%） expression were lower than those with high miR-520f（90.48%，95.24%） and miR-143-3p expression（88.89%，95.56%），the differences were statistically significant（Log Rankχ2=9.270, 5.303, P=0.002，0.021；Log Rnakχ2= 9.079, 6.857，P=0.003, 0.009). Multivariate COX regression analysis showed that lymphatic metastasis（OR=1.680，95%CI：1.423 ～ 1.956）, low expression of miR-520f （OR=1.836，95%CI：1.658 ～ 2.358）and miR-143-3p （OR=2.169，95%CI：2.015 ～ 3.959） were associated with poor prognosis of NSCLC (all P ＜ 0.05). Conclusion　The expression of miR-520f and miR-143-3p was decreased in NSCLC patients，which was associated with the malignant proliferation and invasive behavior of NSCLC cells and the poor prognosis of NSCLC patients.

参考文献/References:

[1] HERBST R S, MORGENSZTERN D, BOSHOFF C. The biology and management of non-small cell lung cancer[J]. Nature, 2018, 553(7689): 446-454.
[2] ARBOUR K C, RIELY G J. Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review[J]. the Journal of the American Medical Association, 2019, 322(8): 764-774.
[3] JIN Xiance, CHEN Yanfan, CHEN Hanbin, et al. Evaluation of tumor-derived exosomal miRNA as potential diagnostic biomarkers for early-stage non-small cell lung cancer using next-generation sequencing[J]. Clinical Cancer Research, 2017, 23(17): 5311-5319.
[4] MESHKAT M, MESRIAN TANHA H, GHAEDI K, et al. Association of a potential functional miR-520f rs75598818 G > A polymorphism with breast cancer[J]. Journal of Genetics, 2018, 97(5): 1307-1313.
[5] SAHAMI-FARD M H, KHEIRANDISH S, SHEIKHHA M H. Expression levels of miR-143- 3p and -424-5p in colorectal cancer and their clinical significance[J]. Cancer Biomarkers : Section a of Disease Markers, 2019, 24(3): 291-297.
[6] 刘旭辉, 王韧, 张献玲, 等. 血清miR-146a 作 为脓毒症诊断标记物的研究[J]． 实用医学杂 志,2017,33(7):1103-1105. LIU Xuhui,WANG Ren,ZHANG Xianling, et al. Serum miR-146a as potential biomarker for sepsis [J]. The Journal of Practical Medicine,2017,33(7):1103-1105.
[7] 仰杰, 尤青海, 孟凡亮. 非小细胞肺癌miR-211 表 达与功能初步研究[J]. 中华肿瘤防治杂志,2018, 25(11)：773-777． YANG Jie,YOU Qinghai,MENG Fanliang,et al. Expression and function of miR-211 in non-small cell lung cancer [J]．Chinese Journal of Cancer Prevention and Treatment, 2018,25(11):773-777．
[8] 崔胜金, 曹朝鹏, 郭伟权, 等．非小细胞肺癌早期诊 断的潜在生物标志物: 血浆miRNA-23a 和miRNA- 451[J]．南方医科大学学报,2019,39(6):705-711. CUI Shengjin,CAO Chaopeng ,GUO Weiquan,et al. Plasma miRNA-23a and miRNA-451 as candidate biomarkers for early diagnosis of non small cell lung cancer: a case-control study [J]. Journal of Southern Medical University,2019,39（6）：705-711．
[9] HARVEY H, PISKAREVA O, CREEVEY L, et al. Modulation of chemotherapeutic drug resistance in neuroblastoma SK-N-AS cells by the neural apoptosis inhibitory protein and miR-520f[J]. International Journal of Cancer, 2015, 136(7): 1579-1588.
[10] HONG S, BI M, CHEN S, et al. MicroRNA-520f suppresses growth of gastric carcinoma cells by target ATPase family AAA domain-containing protein 2 (ATAD2)[J]. Neoplasma, 2016, 63(6): 873-879.
[11] VAN KAMPEN J G M, VAN HOOI J O, JANSEN C F, et al. MiRNA-520f reverses Epithelial-to-Mesenchymal transition by targeting Adam9 and TGFBR2[J]. Cancer Research, 2017, 77(8): 2008-2017.
[12] HARVEY H, PISKAREVA O, CREEVEY L,et al.Modulation of chemotherapeutic drug resistance in neuroblastoma SK-N-AS cells by the neural apoptosis inhibitory protein and miR-520f[J]. Int J Cancer, 2015, 136(7): 1579-1588.
[13] DU Xiaoqin, FAN Wanhu, CHEN Yunru. MicroRNA- 520f inhibits hepatocellular carcinoma cell proliferation and invasion by targeting TM4SF1[J]. Gene, 2018, 657: 30-38.
[14] SHI Haijuan, SHEN Huimin, XU Juan, et al. MiR-143- 3p suppresses the progression of ovarian cancer[J]. American Journal of Translational Research, 2018, 10(3): 866-874.
[15] SUN Xiangran, DAI Guo, YU Ling, et al. MiR-143- 3p inhibits the proliferation, migration and invasion in osteosarcoma by targeting FOSL2[J]. Scientific Reports, 2018, 8(1): 606.
[16] QIAN Yi, TENG Yaoshu, LI Yuandong, et al. MiR-143-3p suppresses the progression of nasal squamous cell carcinoma by targeting Bcl-2 and IGF1R[J]. Biochemical and Biophysical Research Communications, 2019, 518(3): 492-499.
[17] YANG Yanbing, LI Sensen, CAO Juan, et al. RRM2 regulated by LINC00667/miR-143-3p signal is responsible for Non-Small cell lung cancer cell progression[J]. OncoTargets and Therapy, 2019, 12: 9927-9939.

相似文献/References:

[1]张 蕾,任亚女,曾婷婷,等.晚期非小细胞肺癌患者血液实验指标和病理分期等因素对生存时间的影响分析[J].现代检验医学杂志,2016,31(02):83.[doi:10.3969/j.issn.1671-7414.2016.02.025]
　ZHANG Lei,REN Ya-n,ZENG Ting-ting,et al.Analysis of Prognosis Related Factors in Patients with Advanced Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(03):83.[doi:10.3969/j.issn.1671-7414.2016.02.025]
[2]薛鸿涛,任 敏,李长彬.非小细胞肺癌患者放疗前后血清TSGF和CRP的变化及其临床意义[J].现代检验医学杂志,2016,31(02):136.[doi:10.3969/j.issn.1671-7414.2016.02.041]
　XUE Hong-tao,REN Min,LI Chang-bin.Impact and Clinical Significance of Radiotherapy on Serum TSGF and CRP in Patients with Non Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(03):136.[doi:10.3969/j.issn.1671-7414.2016.02.041]
[3]王京伟,李 艳,童永清,等.湖北地区非小细胞肺癌EGFR 基因突变及其意义的研究[J].现代检验医学杂志,2016,31(03):7.[doi:10.3969/j.issn.1671-7414.2016.03.003]
　WANG Jing-wei,LI Yan,TONG Yong-qing,et al.Detection of Epidermal Growth Factor Receptor(EGFR) Mutations and the Significance in Patients with Non-small Cell Lung Cancer(NSCLC)of Hubei Province[J].Journal of Modern Laboratory Medicine,2016,31(03):7.[doi:10.3969/j.issn.1671-7414.2016.03.003]
[4]易甲其,范艳平,周宁加,等.血清PTX-3，CYFRA21-1和TPS在非小细胞肺癌中的变化及临床意义[J].现代检验医学杂志,2015,30(05):58.[doi:10.3969/j.issn.1671-7414.2015.05.018]
　YI Jia-qi,FAN Yan-ping,ZHOU Ning-jia,et al.Changes and Clinical Significance of Serum PTX-3， CYFRA21-1，TPS in Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2015,30(03):58.[doi:10.3969/j.issn.1671-7414.2015.05.018]
[5]钱忠萍,凌 晨,祁松楠,等.围非小细胞肺癌手术期T细胞含量变化的研究[J].现代检验医学杂志,2016,31(05):55.[doi:10.3969/j.issn.1671-7414.2016.05.014]
　QIAN Zhong-ping,LING Chen,QI Song-nan,et al.Content Variation of T Cells in Perioperative Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(03):55.[doi:10.3969/j.issn.1671-7414.2016.05.014]
[6]黎谢梦丹,罗 凯,吴顺芳,等.华南地区非小细胞肺癌患者肿瘤组织EGFR,ALK和ROS1基因突变分析[J].现代检验医学杂志,2017,32(05):16.[doi:10.3969/j.issn.1671-7414.2017.05.005]
　LIXIE Meng-dan,LUO Kai,WU Shun-fang,et al.Mutation Analysis of EGFR,ALK and ROS1 in Tumor Tissues of Patients with Non-Small Cell Lung Cancer in South of China[J].Journal of Modern Laboratory Medicine,2017,32(03):16.[doi:10.3969/j.issn.1671-7414.2017.05.005]
[7]李小龙,白巧艳,陆婉玲.老年非小细胞肺癌患者低分割放疗对凝血功能的影响[J].现代检验医学杂志,2018,33(05):142.[doi:10.3969/j.issn.1671-7414.2018.05.039]
　LI Xiao-long,BAI Qiao-yan,LU Wan-ling.Influence of Hypofractionated High-Dose Radiotherapy on Coagulation Function in Elderly Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(03):142.[doi:10.3969/j.issn.1671-7414.2018.05.039]
[8]郭 华a,齐宗利a,张海祥b,等.非小细胞肺癌组织EGFR/ALK/ROS1基因联合检测的临床意义[J].现代检验医学杂志,2018,33(06):17.[doi:10.3969/j.issn.1671-7414.2018.06.005]
　GUO Huaa,QI Zong-lia,ZHANG Hai-xiangb,et al.Clinical Significance of Combined Detection of EGFR/ALK/ROS1 Genes in Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(03):17.[doi:10.3969/j.issn.1671-7414.2018.06.005]
[9]黄 刚,陈 霏,肇玉博,等.非小细胞肺癌患者血浆miRNA-145和miRNA-221表达与临床特征及术后复发的相关性研究[J].现代检验医学杂志,2019,34(04):40.[doi:10.3969/j.issn.1671-7414.2019.04.010]
　HUANG Gang,CHEN Fei,ZHAO Yu-bo,et al.Study on the Correlation between the Expression of MicroRNA145 and MicroRNA221 in Plasma and Clinical Characteristics and Postoperative Recurrence in Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2019,34(03):40.[doi:10.3969/j.issn.1671-7414.2019.04.010]
[10]蒋玲丽,黄中强,王雪亮,等.表皮生长因子受体（EGFR）基因突变检测质控品制备及应用[J].现代检验医学杂志,2020,35(02):145.[doi:10.3969/j.issn.1671-7414.2020.02.040]
　JIANG Ling-li,HUANG Zhong-qiang,WANG Xue-liang,et al.Development and Application of Quality Control Materials for EpidermalGrowth Factor Receptor （EGFR）Mutation Determination[J].Journal of Modern Laboratory Medicine,2020,35(03):145.[doi:10.3969/j.issn.1671-7414.2020.02.040]

备注/Memo

备注/Memo:
作者简介：张玲玲（1992-），女，本科，初级技师， 研究方向：肿瘤免疫，E-mail：christoph3@163.com。
通讯作者：葛琴（1983-），女，本科，主管技师，研究方向：基础检验技术，E-mail：13912258@163.com。
更新日期/Last Update: 1900-01-01